{
    "nctId": "NCT00045188",
    "briefTitle": "Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of STI571 in Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Objective tumor response (CR + PR), as determined by the RECIST criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic breast cancer\n* Documented expression of CD117 (c-kit) or platelet-derived growth factor receptor\n\n  * Adequate tumor tissue from either the primary tumor and/or metastatic disease available for evaluation\n* Must have received prior chemotherapy with an anthracycline (doxorubicin or epirubicin) and/or taxane (paclitaxel or docetaxel) as adjuvant or for advanced disease\n* At least 1 unidimensionally measurable lesion\n\n  * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n  * Bone disease may not be only source of measurable disease\n  * Pleural or peritoneal ascites are not considered measurable disease\n* No known brain metastases\n* Hormone receptor status:\n\n  * Not specified\n* Female or male\n* Not specified\n* Performance status - ECOG 0-2\n* Performance status - Karnofsky 60-100%\n* More than 12 weeks\n* Absolute neutrophil count at least 1,500/mm\\^3\n* WBC at least 3,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin normal\n* AST or ALT no greater than 2.5 times upper limit of normal\n* Creatinine normal\n* Creatinine clearance at least 60 mL/min\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* No other uncontrolled concurrent illness\n* No ongoing or active infection\n* No prior allergic reaction attributed to compounds of similar chemical or biologic composition to imatinib mesylate\n* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix\n* No psychiatric illness or social situation that would preclude study compliance\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception during and for 1 week after study\n* No concurrent biologic agents\n* No more than 2 prior chemotherapy regimens for metastatic disease\n\n  * Therapy with high-dose regimens or bone marrow transplantation considered 1 regimen\n* At least 4 weeks since prior chemotherapy (6 weeks for carmustine or mitomycin) and recovered\n* No concurrent chemotherapy\n* Prior hormonal therapy for stage IV disease and/or as adjuvant therapy allowed\n* At least 4 weeks since prior radiotherapy and recovered\n* Prior localized radiotherapy that does not influence the signal of the evaluable lesion is allowed\n* At least 2 weeks since prior minor surgery\n* At least 4 weeks since prior major surgery\n* Recovered from prior surgery\n* Low-molecular weight heparin or heparin allowed for anticoagulation\n* No concurrent warfarin\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No concurrent investigational therapies or agents\n* No other concurrent anticancer therapy\n* No concurrent intake of cola, orange juice, grapefruit, or orange or grapefruit sections",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}